Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma.

Full Abstract

The use of immunobiologicals that suppress an overly active immune system in psoriasis carries with it the possibility of cancer development as a result of immunosuppression. Patients with a history of malignancy may be at risk for recurrence when treated with immunosuppressive agents. Moreover, autoimmune diseases, such as psoriasis, have been associated with an increased risk of lymphoma. Therefore, risk-benefit assessments must take into account the clinical severity and treatment of psoriasis. We describe a 59-year-old white man with a history of primary B-cell lymphoma, severe recalcitrant plaque-type psoriasis and psoriatic arthritis, who was started on etanercept for treatment of his psoriasis and psoriatic arthritis. The patient has a long history of remission of his lymphoma. After treatment, the patient experienced significant global improvement with essentially complete remission of the cutaneous lesions and arthritis, and had no recurrence of his lymphoma or other systemic complications while on etanercept after follow-up for > 3 years.

Author information

Author/s: Chong, B F (BF); Wong, H K (HK);

Affiliation: Department of Dermatology, Henry Ford Hospital, Detroit, MI 48202, USA.

Journal and publication information

Publication Type: Case Reports; Journal Article

Journal: Clinical and experimental dermatology (Clin Exp Dermatol), published in England. (Language: eng)

Reference: 2009-Jul; vol 34 (issue 5) : pp e11-3

Dates: Created 2009/06/10; Completed 2009/07/27;

PMID: 19040508, status: MEDLINE (last retrieved date: 8/20/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Follow-Up Studies
Humans
Immunoglobulin G - adverse effects; therapeutic use
Immunosuppressive Agents - adverse effects; therapeutic use
Lymphoma, B-Cell - complications; therapy

Male
Middle Aged
Psoriasis - complications; drug therapy
Receptors, Tumor Necrosis Factor - therapeutic use
Remission Induction

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Immunoglobulin G (0) ; Immunosuppressive Agents (0) ; Receptors, Tumor Necrosis Factor (0) ; TNFR-Fc fusion protein (185243-69-0)

These are the most related articles currently in our database: